<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04744506</url>
  </required_header>
  <id_info>
    <org_study_id>2020-535</org_study_id>
    <nct_id>NCT04744506</nct_id>
  </id_info>
  <brief_title>Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy</brief_title>
  <official_title>Targeted Resection of Axillary Metastatic Lymph Nodes Guided by Tissue Marker Clip After Neoadjuvant Chemotherapy for Breast Cancer: a Multicenter, Prospective and Self-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, prospective, self-controlled study, to evaluate the feasibility&#xD;
      of targeted axillary lymph node resection (TAD) guided by tissue marker clip with methylene&#xD;
      blue single tracer after neoadjuvant chemotherapy in T1-4N1M0 breast cancer patients.&#xD;
      Evaluate the accuracy and false negative rate of TAD, comparing with sentinel lymph node&#xD;
      biopsy, and explore a new axillary-preserving mode after neoadjuvant chemotherapy for breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>False negative rate (FNR) of targeted axillary lymph node resection</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>False negative rate (FNR) of targeted axillary lymph node resection of breast cancer with methylene blue single tracer after neoadjuvant chemotherapy for T1-3N1M0 breast cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">332</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Surgery</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>TAD ARM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Marker Clip</intervention_name>
    <description>Tissue Marker Clip Placed in Metastatic Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)</description>
    <arm_group_label>TAD ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. breast cancer with axillary lymph node metastasis confirmed by puncture pathology&#xD;
             (T1-3N1M0)&#xD;
&#xD;
          2. accord with the indications of neoadjuvant chemotherapy for breast cancer&#xD;
&#xD;
          3. informed consent has been signed&#xD;
&#xD;
          4. Preoperative anesthesia assessment is low to medium risk (ASA score)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are absolute and relative contraindications of chemotherapy&#xD;
&#xD;
          2. Refuse surgery or can't tolerate surgery&#xD;
&#xD;
          3. Unable to cooperate or unwilling to place Marker&#xD;
&#xD;
          4. Pregnant women&#xD;
&#xD;
          5. Do not have full capacity for behavior, such as mental patients, drug dependence,&#xD;
             anxiety and so on&#xD;
&#xD;
          6. Diabetes patients who are difficult to control&#xD;
&#xD;
          7. Excessive smokers&#xD;
&#xD;
          8. high risk of anesthesia&#xD;
&#xD;
          9. Any serious complications are not suitable for patients participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Huang, Dr</last_name>
      <phone>+86 0571 87784642</phone>
      <email>fhchenwz@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04744506/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04744506/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

